Unknown

Dataset Information

0

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes-exploratory analysis of the Clalit registry.


ABSTRACT: Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a 'study-cohort' (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a 'general 21-gene-tested BC-cohort' (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1-7.1) years; the second BC was ipsilateral in 68%. Patient/tumor characteristics of the first- and second-BC in the 'study-cohort' were similar, except for the RS which was higher in the second BC (median [IQR]: 23 [17-30] vs 17 [14-22], p < 0.001). Overall, 56 patients had follow-up data, of whom 5 experienced distant recurrence (2 RS 11-25 patients and 3 RS 26-100 patients). Studies exploring the prognostic utility of the RS in this setting are warranted.

SUBMITTER: Shachar SS 

PROVIDER: S-EPMC10541873 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes-exploratory analysis of the Clalit registry.

Shachar Shlomit S SS   Leviov Michelle M   Yerushalmi Rinat R   Drumea Karen K   Tokar Margarita M   Soussan-Gutman Lior L   Bareket-Samish Avital A   Sonnenblick Amir A   Ben-Baruch Noa N   Evron Ella E   Gal-Yam Einav Nili EN   Paluch-Shimon Shani S   Bar-Sela Gil G   Goldvaser Hadar H   Stemmer Salomon M SM  

NPJ breast cancer 20230930 1


Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a 'study-cohort' (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a 'general 21-gene-tested BC-cohort' (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1-7.1)  ...[more]

Similar Datasets

| S-EPMC5620441 | biostudies-literature
| S-EPMC7755430 | biostudies-literature
| S-EPMC2947682 | biostudies-literature
| S-EPMC5387031 | biostudies-literature
| S-EPMC7377026 | biostudies-literature
| S-EPMC5591181 | biostudies-literature
| S-EPMC5996978 | biostudies-literature
| S-EPMC2848890 | biostudies-literature
| S-EPMC5241446 | biostudies-literature
| S-EPMC5909985 | biostudies-literature